OncoMatch/Clinical Trials/NCT06034561
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Is NCT06034561 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Bortezomib for acute lymphoblastic leukemia, in relapse.
Treatment: Bortezomib — This is a interventional phase II study aiming to examine the complete response rate of a bortezomib-based salvage regimen in adults with refractory or relapsed acute lymphoblastic leukemia (ALL), seeking to compare outcomes with the available literature and with our historical data on relapsed/refractory ALL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: bortezomib (bortezomib)
Prior exposure to bortezomib
Cannot have received: anthracycline
Exception: lifetime exposure ≤400mg/m2
Patients with more than 400mg/m2 lifetime exposure of anthracycline
Lab requirements
Kidney function
Creatinine ≤2.5 mg/dl
Liver function
Total bilirubin ≤2x ULN; transaminases ≤5x ULN
Cardiac function
No heart failure NYHA Class III or IV
Total bilirubin>2x upper limit of normal (ULN); Transaminases>5x ULN; Creatinine>2,5 mg/dl; Heart failure New York Heart Association (NYHA) Class III or IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06034561 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bortezomib, anthracycline disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 60 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages